• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

微小RNA-223-3p作为甲状腺乳头状癌中细胞增殖和侵袭新启动子的特征分析

Characterization of microRNA-223-3p as a novel promoter of cell proliferation and invasion in papillary thyroid carcinoma.

作者信息

Pan Xinghe, Liu Junliang, Zhang Yitong, Sun Chenglin, Li You, Guo Hongpeng

机构信息

Department of General Surgery Central Hospital Affiliated to Shenyang Medical College Shenyang Liaoning China.

出版信息

J Cell Commun Signal. 2024 Dec 19;19(1):e12057. doi: 10.1002/ccs3.12057. eCollection 2025 Mar.

DOI:10.1002/ccs3.12057
PMID:39712860
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11658962/
Abstract

Papillary thyroid carcinoma (PTC), the most common thyroid cancer, has been linked to various molecular alterations. This study focuses on microRNA-223-3p, whose upregulated expression in PTC tissues appears to enhance tumor growth and cellular dysfunctions. Our findings demonstrate that microRNA-223-3p significantly promotes cell proliferation, invasion, and migration and induces epithelial-mesenchymal transition (EMT). Additionally, neurofibromatosis type 2 (NF2) is identified as a direct target, suggesting that microRNA-223-3p could be crucial in PTC pathogenesis and may offer a target for therapeutic intervention.

摘要

乳头状甲状腺癌（PTC）是最常见的甲状腺癌，与多种分子改变有关。本研究聚焦于微小RNA-223-3p，其在PTC组织中的表达上调似乎会促进肿瘤生长和细胞功能障碍。我们的研究结果表明，微小RNA-223-3p显著促进细胞增殖、侵袭和迁移，并诱导上皮-间质转化（EMT）。此外，2型神经纤维瘤病（NF2）被确定为直接靶点，这表明微小RNA-223-3p在PTC发病机制中可能起关键作用，并可能为治疗干预提供一个靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11ac/11658962/5eda60551771/CCS3-19-e12057-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11ac/11658962/53a1406f96cf/CCS3-19-e12057-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11ac/11658962/103bae9bb37d/CCS3-19-e12057-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11ac/11658962/5b0586eb8d50/CCS3-19-e12057-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11ac/11658962/223ae5f7e243/CCS3-19-e12057-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11ac/11658962/0c06c5543a00/CCS3-19-e12057-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11ac/11658962/5eda60551771/CCS3-19-e12057-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11ac/11658962/53a1406f96cf/CCS3-19-e12057-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11ac/11658962/103bae9bb37d/CCS3-19-e12057-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11ac/11658962/5b0586eb8d50/CCS3-19-e12057-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11ac/11658962/223ae5f7e243/CCS3-19-e12057-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11ac/11658962/0c06c5543a00/CCS3-19-e12057-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11ac/11658962/5eda60551771/CCS3-19-e12057-g002.jpg

相似文献

1
Characterization of microRNA-223-3p as a novel promoter of cell proliferation and invasion in papillary thyroid carcinoma.微小RNA-223-3p作为甲状腺乳头状癌中细胞增殖和侵袭新启动子的特征分析
J Cell Commun Signal. 2024 Dec 19;19(1):e12057. doi: 10.1002/ccs3.12057. eCollection 2025 Mar.
2
MicroRNA-520a-3p suppresses epithelial-mesenchymal transition, invasion, and migration of papillary thyroid carcinoma cells via the JAK1-mediated JAK/STAT signaling pathway.miR-520a-3p 通过 JAK1 介导的 JAK/STAT 信号通路抑制甲状腺乳头状癌细胞的上皮-间充质转化、侵袭和迁移。
J Cell Physiol. 2019 Apr;234(4):4054-4067. doi: 10.1002/jcp.27199. Epub 2018 Sep 12.
3
MicroRNA-146b-3p Promotes Cell Metastasis by Directly Targeting in Human Papillary Thyroid Cancer.miR-146b-3p 通过直接靶向在人甲状腺乳头状癌中促进细胞转移。
Thyroid. 2018 Dec;28(12):1627-1641. doi: 10.1089/thy.2017.0626. Epub 2018 Oct 27.
4
MicroRNA-142-3P suppresses the progression of papillary thyroid carcinoma by targeting FN1 and inactivating FAK/ERK/PI3K signaling.微小 RNA-142-3P 通过靶向 FN1 并使 FAK/ERK/PI3K 信号失活来抑制甲状腺乳头状癌的进展。
Cell Signal. 2023 Sep;109:110792. doi: 10.1016/j.cellsig.2023.110792. Epub 2023 Jul 3.
5
MicroRNA-99a-3p/GRP94 axis affects metastatic progression of human papillary thyroid carcinoma by regulating ITGA2 expression and localization.miR-99a-3p/GRP94 轴通过调控 ITGA2 的表达和定位影响人甲状腺乳头状癌细胞的转移进展。
Acta Biochim Biophys Sin (Shanghai). 2021 Dec 8;53(12):1650-1661. doi: 10.1093/abbs/gmab147.
6
microRNA-599 promotes apoptosis and represses proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma cells via downregulation of Hey2-depentent Notch signaling pathway.miRNA-599 通过下调 Hey2 依赖性 Notch 信号通路促进甲状腺乳头状癌细胞凋亡，抑制增殖和上皮间质转化。
J Cell Physiol. 2020 Mar;235(3):2492-2505. doi: 10.1002/jcp.29154. Epub 2019 Sep 29.
7
Upregulation of microRNA-143-3p induces apoptosis and suppresses proliferation, invasion, and migration of papillary thyroid carcinoma cells by targeting MSI2.上调 microRNA-143-3p 通过靶向 MSI2 诱导甲状腺乳头状癌细胞凋亡并抑制其增殖、侵袭和迁移。
Exp Mol Pathol. 2020 Feb;112:104342. doi: 10.1016/j.yexmp.2019.104342. Epub 2019 Nov 15.
8
Long non-coding RNA BRM promotes proliferation and invasion of papillary thyroid carcinoma by regulating the microRNA-331-3p/SLC25A1 axis.长链非编码RNA BRM通过调控微小RNA-331-3p/SLC25A1轴促进甲状腺乳头状癌的增殖和侵袭。
Oncol Lett. 2020 Apr;19(4):3071-3078. doi: 10.3892/ol.2020.11418. Epub 2020 Feb 20.
9
MicroRNA-203 restrains epithelial-mesenchymal transition, invasion and migration of papillary thyroid cancer by downregulating AKT3.MicroRNA-203 通过下调 AKT3 抑制甲状腺乳头状癌细胞的上皮-间充质转化、侵袭和迁移。
Cell Cycle. 2020 May;19(10):1105-1121. doi: 10.1080/15384101.2020.1746490. Epub 2020 Apr 19.
10
Exosomal circular RNA hsa_circ_007293 promotes proliferation, migration, invasion, and epithelial-mesenchymal transition of papillary thyroid carcinoma cells through regulation of the microRNA-653-5p/paired box 6 axis.外泌体环状 RNA hsa_circ_007293 通过调控微小 RNA-653-5p/配对盒 6 轴促进甲状腺乳头状癌细胞的增殖、迁移、侵袭和上皮-间充质转化。
Bioengineered. 2021 Dec;12(2):10136-10149. doi: 10.1080/21655979.2021.2000745.

本文引用的文献

1
Molecular mechanisms and therapeutic applications of huaier in breast cancer treatment.槐耳在乳腺癌治疗中的分子机制及治疗应用
Front Pharmacol. 2024 Jan 12;14:1269096. doi: 10.3389/fphar.2023.1269096. eCollection 2023.
2
Concurrent Anaplastic and Papillary Thyroid Carcinoma Manifesting as a Thyrocutaneous Fistula.表现为甲状腺皮肤瘘的同时性间变性和乳头状甲状腺癌
Cureus. 2023 Dec 5;15(12):e49990. doi: 10.7759/cureus.49990. eCollection 2023 Dec.
3
Global incidence and prevalence of differentiated thyroid cancer in childhood: systematic review and meta-analysis.
全球儿童分化型甲状腺癌的发病率和患病率：系统评价和荟萃分析。
Front Endocrinol (Lausanne). 2023 Sep 19;14:1270518. doi: 10.3389/fendo.2023.1270518. eCollection 2023.
4
Exosomal miRNA-223-3p derived from tumor associated macrophages promotes pulmonary metastasis of breast cancer 4T1 cells.源自肿瘤相关巨噬细胞的外泌体miRNA-223-3p促进乳腺癌4T1细胞的肺转移。
Transl Oncol. 2023 Sep;35:101715. doi: 10.1016/j.tranon.2023.101715. Epub 2023 Jun 16.
5
Clinical outcomes of ultrasound-guided radiofrequency ablation for solitary T1N0M0 papillary thyroid carcinoma: A retrospective study with more than 5 years of follow-up.超声引导下射频消融治疗单发 T1N0M0 期甲状腺乳头状癌的临床疗效：一项超过 5 年随访的回顾性研究。
Cancer. 2023 Aug 15;129(16):2469-2478. doi: 10.1002/cncr.34802. Epub 2023 Apr 15.
6
Molecular mechanism and diagnostic marker investigation of endoplasmic reticulum stress on periodontitis.探讨内质网应激在牙周炎中的分子机制和诊断标志物。
BMC Oral Health. 2023 Mar 9;23(1):135. doi: 10.1186/s12903-023-02822-5.
7
Cancer-associated fibroblasts in papillary thyroid carcinoma.甲状腺乳头状癌中的癌相关成纤维细胞。
Clin Exp Med. 2023 Oct;23(6):2209-2220. doi: 10.1007/s10238-023-00998-2. Epub 2023 Jan 30.
8
Comparison of Lobectomy vs Total Thyroidectomy for Intermediate-Risk Papillary Thyroid Carcinoma With Lymph Node Metastasis.对比淋巴结转移的中危甲状腺乳头状癌行 lobectomy 与 total thyroidectomy。
JAMA Surg. 2023 Jan 1;158(1):73-79. doi: 10.1001/jamasurg.2022.5781.
9
Optical diagnostic imaging and therapy for thyroid cancer.甲状腺癌的光学诊断成像与治疗
Mater Today Bio. 2022 Sep 26;17:100441. doi: 10.1016/j.mtbio.2022.100441. eCollection 2022 Dec 15.
10
Papillary thyroid carcinoma: the impact of histologic vascular invasion.甲状腺乳头状癌：组织学血管侵犯的影响。
Minerva Endocrinol (Torino). 2024 Mar;49(1):69-75. doi: 10.23736/S2724-6507.22.03749-6. Epub 2022 Oct 17.